<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857530</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2013-066-01</org_study_id>
    <nct_id>NCT02857530</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia</brief_title>
  <official_title>Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Recombinant human thrombopoietin in patients with severe aplastic
      anemia and very severe aplastic anemia, a randomized, double-blind, placebo-controlled, II
      phase, multi-center clinical research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      rhTPO
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to platelet transfusion independence in patients at 6 month</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to patients achieve a platelet count 30×10^9/L, 50×10^9/L or100×10^9/L</measure>
    <time_frame>up to 1year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate up to 1 year after Immunosupressive therapy.</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Megakaryocyte, granulocyte and erythrocyte recovery in bone marrow up to 1 year after IST.</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to red blood cell/platelet transfusion independence in patients up to 1 year after IST</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieve red blood cell/platelet transfusion independence at 3, 6, 9 and 12 months after IST.</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervals of red blood cell/platelet transfusion up to 1 year after IST.</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reticulocyte count of patients up to 1 year after IST.</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization days of patients.</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median hematopoietic response rate up to 1 year after IST.</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Anemia, Aplastic</condition>
  <arm_group>
    <arm_group_label>rhTPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTPO injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>without rhTPO injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhTPO</intervention_name>
    <description>rhTPO</description>
    <arm_group_label>rhTPO</arm_group_label>
    <other_name>Recombinant Human Thrombopoietin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>without rhTPO</description>
    <arm_group_label>control</arm_group_label>
    <other_name>without Recombinant Human Thrombopoietin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Have severe or very severe aplastic anemia

        Exclusion Criteria:

          -  Have diagnosis of Fanconi anemia

          -  Have infection not adequately responding to appropriate therapy

          -  Have Paroxysmal Nocturnal Hemoglobinuria (PNH) clone size in neutrophils of greater
             than or equal to 50%

          -  Have creatinine and/or blood urea nitrogen (BUN) ≥2 times the upper limit of normal

          -  Have serum bilirubin ≥ 1.5 times the upper limit of normal, or ≥4.0 times the upper
             limit of normal if the patient has been treated with Anti-Thymocytes globulin（ATG）
             within three weeks of screening.

          -  Have glutamic-oxaloacetic transaminase （AST） and/or glutamic-pyruvic transaminase
             （ALT） ≥ 3 times the upper limit of normal

          -  Are female and are nursing or pregnant or are unwilling to take oral contraceptives or
             refrain from pregnancy if of childbearing potential

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or greater

          -  Have had other Thrombopoietin (TPO-R) agonists medication in the previous 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ZONGHONG SHAO, MD.</last_name>
    <phone>8613702036467</phone>
    <email>shaozonghong@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zonghong Shao</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ZONGHONG SHAO, MD.</last_name>
      <phone>13702036467</phone>
      <email>shaozonghong@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>ZhongHong Shao</investigator_full_name>
    <investigator_title>head of department of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

